PISCATAWAY, NJ -
Sabinsa Corporation’s founder Dr. Muhammed Majeed
and his scientific staff have co-authored a booklet entitled
"Boswellin® : Redefining
Our Standards" to recommend that the supplement industry
redefine its references to this ingredient.
In 1991, Sabinsa Corporation pioneered Boswellin®
, a standardized extract containing boswellic acids, for
the U.S. market. The prevalently used nomenclature for the
anti-inflammatory constituents in Boswellia serrata extracts
is "boswellic acids". Standardized extracts currently
marketed are labeled as containing about 50% to70% boswellic
acids. Isolation of the individual components and detailed
analytical methodology, developed by Sabinsa Corporation,
have now provided the necessary data to redefine this ingredient.
Change the phrase "boswellic
acids" to "total organic acids" from Boswellia
serrata.
This is applicable if you are
using a 65-70% standardized organic acids raw material.
The daily dose is to be 200 mg x 3 times, based on "total
organic acids".
The term "pure boswellic
acids" could also be used with the indication of the
milligrams in each dosage form. The daily dose in this case
will be approximately 50 mg x 3 times, based on four standardized
"pure boswellic acids".
The booklet explains the science behind the
proposed changes, and is available through Sabinsa Corporation,
70 Ethel Road West, Unit 6, Piscataway, NJ 08854 or 594
South American Way, Payson, Utah 84651.
Sabinsa Corporation which pioneered the introduction
of several Ayurvedic herbal extracts and specialty fine
chemicals used for nutritional, pharmaceutical and food
products. Sabinsa distinguishes itself by its extensive
research support for its customers and products, and the
scientific credentials of its key technical staff.
|
